What question did this study set out to answer?

To estimate the risk of rhabdomyolysis associated with statin and fibrate therapy in patients using these lipid-lowering drugs.

November 30, 2004JAMA

Incidence of Hospitalized Rhabdomyolysis in Patients Treated With Lipid-Lowering Drugs

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial estimates rhabdomyolysis incidence in patients using statins and fibrates, indicating varying risk levels.

To estimate the risk of rhabdomyolysis associated with statin and fibrate therapy in patients using these lipid-lowering drugs.
Established drug-specific cohorts from claims data of 252,460 patients across 11 managed care health plans.
Classified treatment periods as monotherapy or combined statin-fibrate therapy.
Measured incidence rates of rhabdomyolysis per 10,000 person-years.
24 cases of hospitalized rhabdomyolysis occurred during treatment; incidence for atorvastatin, pravastatin, simvastatin was 0.44 (95% CI, 0.20-0.84).
Combined therapy with cerivastatin and fibrate had a high incidence of 1035 (95% CI, 389-2117).
Number needed to treat to observe 1 case was 22,727 for statin monotherapy and lower for combinations.

David J. Graham (2004) studied this question.

View Full Paper

Ask AI

Bookmark